Multiple Pulmonary Metastases from Renal Cell Carcinoma Treated Effectively by Recombinant Interleukin-2

1990 ◽  
Vol 45 (1) ◽  
pp. 54-57
Author(s):  
Shinichi Ikemoto ◽  
Tatsuya Nakatani ◽  
Kazunobu Sugimura ◽  
Hiroshi Tanaka ◽  
Masanobu Maekawa
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Pulmonary Metastases ◽  
Interleukin 2 ◽  
Recombinant Interleukin 2

Review of inhaled recombinant interleukin-2 (rIL-2) in patients with renal cell carcinoma with pulmonary metastases

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4756-4756
Author(s):  
G. Michelson ◽  
E. Esteban ◽  
C. Garcia-Giron ◽  
A. Jimenez-Lacave ◽  
A. Canelas ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Pulmonary Metastases ◽  
Interleukin 2 ◽  
Recombinant Interleukin 2

Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2

2007 ◽  
Vol 18 (3) ◽  
pp. 291-296 ◽  
Author(s):  
Emilio Esteban-Gonz??lez ◽  
Joaqu??n Carballido ◽  
V??ctor Navas ◽  
Zoila Torregrosa ◽  
Antonio Mu??oz ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Retrospective Review ◽  
Renal Cell ◽  
Pulmonary Metastases ◽  
Interleukin 2 ◽  
Recombinant Interleukin 2

Immunologic study of human recombinant interleukin-2 (low dose) in patients with advanced renal cell carcinoma

Urology ◽  
1989 ◽  
Vol 33 (3) ◽  
pp. 219-225 ◽  
Author(s):  
Ken Marumo ◽  
Junro Muraki ◽  
Munehisa Ueno ◽  
Masaaki Tachibana ◽  
Nobuhiro Deguchi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Low Dose ◽  
Interleukin 2 ◽  
Advanced Renal Cell Carcinoma ◽  
Recombinant Interleukin 2

Subcutaneous Recombinant Interleukin-2 and a-Interferon in Patients with Advanced Renal Cell Carcinoma: Results of a Multicenter Phase II Study

1993 ◽  
Vol 8 (4) ◽  
pp. 289-300 ◽  
Author(s):  
Jens Atzpodien ◽  
Hartmut Kirchner ◽  
Peter de Mulder ◽  
Heiner Bodenstein ◽  
Tim Olivera ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Interleukin 2 ◽  
Advanced Renal Cell Carcinoma ◽  
Multicenter Phase ◽  
Recombinant Interleukin 2

Medical Treatment of Advanced Renal Cell Carcinoma

1992 ◽  
Vol 59 (6) ◽  
pp. 54-56
Author(s):  
M. Giusto ◽  
F. Tuccia ◽  
D. Da Corte ◽  
C. Puccetti
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Response Rates ◽  
Advanced Renal Cell Carcinoma ◽  
Innovative Strategies ◽  
Recombinant Interleukin 2 ◽  
History Of

Therapy for disseminated renal cell carcinoma is a major problem, as it's almost completely resistant to standard therapeutic approaches such as chemotherapy or radiotherapy. The search for innovative strategies has led to new concepts based on the assumption that cellular or soluble mediators of the immune system can be rendered cytotoxic or cytostatic for renal cell cancer. With partial response rates of ca. 100% and very promising global response rates, biotherapies are in progress. A number of clinical trials have been perfomed employing systemic administration of interferon (rIFN-) alone or in combination with cytostatic agents, human recombinant interleukin-2 (rlL-2), and, more recently, immunomodulatory agents such as lymphokine-activated killer (LAK) cells: these substances have been demonstrated to be a treatment of choice for advanced renal cell carcinoma, even if they seem unable to modify the natural history of the disease.

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

1988 ◽  
Vol 6 (5) ◽  
pp. 839-853 ◽  
Author(s):  
S L Topalian ◽  
D Solomon ◽  
F P Avis ◽  
A E Chang ◽  
D L Freerksen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Advanced Cancer ◽  
Adoptive Immunotherapy ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Lak Cells ◽  
Recombinant Interleukin 2 ◽  
Infiltrating Lymphocytes

Clinical investigations using the adoptive transfer of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) to treat patients with advanced cancer have yielded encouraging results. We have thus sought ways to enhance the effectiveness of adoptive immunotherapy while minimizing its toxic side effects. Murine experiments have identified tumor-infiltrating lymphocytes (TIL) as killer cells more effective than LAK cells and less dependent on adjunctive systemically administered IL-2 to mediate antitumor effects. Accordingly, we performed a pilot protocol to investigate the feasibility and practicality of administering IL-2-expanded TIL to humans with metastatic cancers. Twelve patients, including six with melanoma, four with renal cell carcinoma, one with breast carcinoma, and one with colon carcinoma, were treated with varying doses and combinations of TIL (8.0 X 10(9) to 2.3 X 10(11) cells per patient), IL-2 (10,000 to 100,000 U/kg three times daily to dose-limiting toxicity), and cyclophosphamide (CPM) (up to 50 mg/kg). Two partial responses (PR) to therapy were observed: pulmonary and mediastinal masses regressed in a patient with melanoma, and a lymph node mass regressed in a patient with renal cell carcinoma. One additional patient with breast cancer experienced a partial regression of disease in lymph nodal and cutaneous sites with complete elimination of malignant cells from a pleural effusion, although cutaneous disease recurred at 4 weeks. The toxicities of therapy were similar to those ascribed to IL-2; no toxic effects were directly attributable to TIL infusions. In five of six melanoma patients, TIL demonstrated lytic activity specific for the autologous tumor target in short-term chromium-release assays, distinct from the nonspecific lytic activity characteristic of LAK cells. This study represents an initial attempt to identify and use lymphocyte subsets with enhanced tumoricidal capacity in the adoptive immunotherapy of human malignancies.

Sign in / Sign up

Export Citation Format

Share Document